Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Cytosorbents Cor (NQ: CTSO )

7.620 USD -0.010 (-0.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 118,773
Open 7.690
Bid (Size) 7.400 (10)
Ask (Size) 7.750 (2)
Prev. Close 7.630
Today's Range 7.470 - 7.720
52wk Range 7.130 - 11.68
Shares Outstanding 43,319,297
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
CytoSorbents to Report Second Quarter 2021 Operating and Financial Results
CytoSorbents Corporation (NASDAQ: CTSO) a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer... 
From PR Newswire
CytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery
CytoSorbents Corporation (NASDAQ: CTSO) announces the full approval of its Investigational Device Exemption (IDE) application to conduct the pivotal STAR-T (Safe and Timely Antithrombotic Removal –... 
From PR Newswire

Performance

YTD
-8.96%
-8.96%
1 Month
-0.13%
-0.13%
3 Month
-15.71%
-15.71%
6 Month
-14.09%
-14.09%
1 Year
-19.70%
-19.70%

More News

Read More
CytoSorbents Appoints Terri Anne Powers, IRC as Vice President of Investor Relations and Corporate Communications
From PR Newswire
CytoSorbents to Present at the Jefferies Virtual Healthcare Conference
From PR Newswire
CytoSorb® Registered and Commercially Available in Singapore
From PR Newswire
CytoSorbents to Present at the UBS Global Healthcare Virtual Conference and Oppenheimer MedTech, Tools and Diagnostic Summit
From PR Newswire
NIRI Chicago Elects 2021-2022 Officers and Directors
From Business Wire News Releases
CytoSorbents Awarded $1.5 Million Sequential Phase II SBIR Contract to Advance the Treatment of Severe Hyperkalemia in Traumatic Injury
From PR Newswire
CytoSorbents Reports First Quarter 2021 Financial and Operational Results
From PR Newswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Tags Pre/Market Outlook Benzinga AKTX
From Benzinga
CytoSorbents Shares Are Trading Higher On Launch Of Trial On Ticagrelor Removal During Cardiothoracic Surgery
Tags News acute coronary syndrome Market News
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.